Related Experiment Video
Updated: Jun 3, 2026
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Engineering dendritic cells to enhance cancer immunotherapy
Jeanette E Boudreau1, Aude Bonehill, Kris Thielemans
1Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Summary
Cancer immunotherapy uses gene-modified dendritic cells (DCs) as a vaccine platform to activate T-cells against tumors. Strategies focus on enhancing antigen presentation and costimulation for improved cancer vaccine efficacy.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer immunotherapy seeks to control tumor growth via T-cell responses targeting tumor-associated antigens.
- T-cell activation requires antigen presentation, costimulation, and soluble factors for immune response polarization.
- Dendritic cells (DCs) are ideal cancer vaccine platforms due to their ability to provide all three T-cell activation signals.
Purpose of the Study:
- To review progress in developing dendritic cell (DC)-based cancer vaccines using genetic modification.
- To discuss strategies for enhancing antigen presentation, costimulation, and cytokine production in DC vaccines.
- To explore the impact of gene modification on DC vaccine activation of natural killer (NK) and B-cells.
Main Methods:
- Review of genetic modification strategies for DC-based cancer vaccines, including RNA, DNA, and recombinant viruses.
- Analysis of methods to enhance antigen presentation and costimulation.
- Examination of DC-based vaccine effects on NK and B-cell activation.
Main Results:
- Gene modification of DCs using RNA, DNA, and viruses shows promise for cancer vaccine development.
- Strategies exist to control and enhance antigen presentation, costimulation, and cytokine production.
- DC-based vaccines can activate NK and B-cells, with gene modification impacting these responses.
Conclusions:
- Gene-modified DCs represent a promising platform for cancer vaccines, requiring optimization for clinical efficacy.
- Further research into DC manipulation is necessary to improve the clinical outcomes of DC-based cancer immunotherapies.
- Understanding the interplay between gene modification strategies and immune cell activation (T-cells, NK, B-cells) is crucial for advancing DC vaccines.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...